Key statistics
As of last trade Kalvista Pharmaceuticals Inc (KALV:NMQ) traded at 15.41, -18.89% below its 52-week high of 19.00, set on Jan 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 15.67 |
|---|---|
| High | 15.88 |
| Low | 15.27 |
| Bid | 15.40 |
| Offer | 15.49 |
| Previous close | 16.06 |
| Average volume | 591.97k |
|---|---|
| Shares outstanding | 50.55m |
| Free float | 49.74m |
| P/E (TTM) | -- |
| Market cap | 811.77m USD |
| EPS (TTM) | -3.95 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 16:27 GMT.
More ▼
- KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
- KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
- KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
- KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
More ▼
